M Selbovitz

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Background Recovery of gut mucosal immune system is slow and incomplete during HAART therapy, leading to elevated inflammation rates, increased mitochondrial damage and the pathogenesis of replicatively competent escape mutations. A recent study of Ganeden BC30, Bacillus coagulans GBI-30, demonstrated safety, increased CD4+ counts in patients on HARRT, and(More)
  • 1